Clinical Trials Browser

Advanced Gastric Cancer

Cholangiocarcinoma

Gastrointestinal Stromal Tumors

Salivary Gland Neoplasms

Gastric Adenocarcinoma

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Advanced Biliary Tract Carcinoma

Gestational Trophoblastic Disease

Advanced Primary Liver Cancer

Adenocarcinoma

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Malignant Neoplasms of Digestive Organs

Breast Neoplasms, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Liver Neoplasms

Squamous Cell Carcinoma of Head and Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Small Cell Lung Cancer Extensive Stage

Small Cell Lung Cancer Limited Stage

Advanced Gastric Cancer

Immunotherapy

Stomach Neoplasms

Triple Negative Breast Neoplasms

Stomach Neoplasms

Metastatic Castration Resistant Prostate Cancer

Stomach Neoplasms

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Endometrial Neoplasms

Esthesioneuroblastoma, Olfactory

Neuroendocrine Tumors

Clinical Trials

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

FAD-HCC-001

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

SHR-2554

SPARE-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

ACADEMY

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

FASCINATE-N

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

TASK-05

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

BIOVAS

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer

A-CAPE

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors